The neuroprotective effect of quercetin administration was evaluated on mice of the triple transgenic AD model (i.e., with three mutations associated with hereditary AD, namely, APP-Swedish, MAPT-P301L and PSEN1-M146V) aged 21–24 months (for mice, this is an advanced age) [274]. Here, MAPT is linked to Alzheimer disease.